Aeon Biopharma Inc

NYSE American:AEONUnited States

Nov 13, 2024

Show headlines and story abstract

• AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: AEON
  deficit $ 4,004 $ 6,845 ========== ========= AEON BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (in thousands, except share and per share data) Three Months Ended Nine Months Ended September 30, September 30, ----------------------------------------- ------------------------------------------- 2024 2023 2024 2023 ------------ --------------------------- ------------ ----------------------------- Successor Successor July 22 to Predecessor July 22 to Predecessor September July 1 to September January 1 to Successor 30 July 21 Successor 30 July 21 ----------- ----------- ------------ ----------- ----------- -------------- Operating expenses: Selling, general and administrative $ 3,044 $ 5,265 $ 1,055 $ 11,014 $ 5,265 $ 9,841 Research and development 972 6,388 1,573 11,144 6,388 19,803 Acquired in-process research and development -- 348,000 -- -- 348,000 -- Change in fair value of contingent consideration -- (75,939) -- (97,464) (75,939) -- ---------- ---------- ----------- ---------- ---------- ----------- Total operating costs and expenses 4,016 283,714 2,628 (75,306) 283,714 29,644 ---------- ---------- ----------- ---------- ---------- ----------- (Loss) income from operations (4,016) (283,714) (2,628) 75,306 (283,714) (29,644) Other (loss) income: Change in fair value of convertible notes (1,878) -- (13,249) (170) -- (19,359) Change in fair value of warrants (377) 1,593 -- (15,376) 1,593 -- Income (loss) on embedded forward purchase agreements and derivative liabilities, net 81 (15,776) (11,789) (19,931) (15,776) (11,789) Other income, net 19 186 5 94 186 114 ---------- ---------- ----------- ---------- ---------- ----------- Total other loss, net (2,155) (13,997) (25,033) (35,383) (13,997) (31,034) ---------- ---------- ----------- ---------- ---------- ----------- (Loss) income before taxes (6,171) (297,711) (27,661) 39,923 (297,711) (60,678) Income taxes -- -- -- -- -- -- ---------- ---------- ----------- ---------- ---------- ----------- Net (loss) income $ (6,171) $ (297,711) $ (27,661) $ 39,923 $ (297,711) $ (60,678) ========== ========== =========== ========== ========== =========== Basic net (loss) income per share $ (0.16) $ (8.01) $ (0.20) $ 1.04 $ (8.01) $ (0.44) ========== ========== =========== ========== ========== =========== Diluted net (loss) income per share $ (0.16) $ (8.01) $ (0.20) $ 0.97 $ (8.01) $ (0.44) ========== ========== =========== ========== ========== =========== Weighted average shares of common stock outstanding used to compute basic net (loss) income per share 39,515,292 37,159,600 138,848,177 38,545,882 37,159,600 138,848,177 ========== ========== =========== ========== ========== =========== Weighted average shares of common stock outstanding used to compute diluted net (loss) income per share 39,515,292 37,159,600 138,848,177 41,318,831 37,159,600 138,848,177 ========== ========== =========== ========== ========== ===========
  

• Press Release: AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: AEON